Illumina urged shareholders to reject Carl Icahn’s board nominees as the proxy fight heats up. The DNA sequencing company said in a preliminary proxy statement that Carl Icahn’s board nominees would “threaten the progress” of its core business. (CNBC)
Daiichi Sankyo and Confo Therapeutics made a $183 million discovery deal focused on small molecule antagonists for an undisclosed target related to central nervous system diseases. It’s Confo’s latest move to partner with a big pharma, after most recently signing a licensing deal with Eli Lilly. (Endpoints News)
Scientist Lisa Barnes said she is on a quest to make Alzheimer’s research more diverse, in an area with many disparities. Barnes has been leading the Minority Aging Research Study to learn more about how the disease impacts people of color, as the number of aging Black people is expected to double in the next decades. (STAT)
GSK saw peak sales of more than $500 million for a drug to treat yeast infections that it licensed from U.S. biotech company Scynexis. The pill, Brexafemme, made just $1.6 million in revenues in the third quarter of last year, according to the most recent financial results from Scynexis, which specializes in anti-fungal treatments. (Reuters)
Meet the TikTok witchdoctors cashing in on broken healthcare. Business is booming for traditional healers who claim they can cure illness, improve love lives and advance careers. (The Telegraph)
